Citations

Clear

6273 citation(s) found for "To, Andrew".

Enhancing the utility of placental pathology reports for clinical use
Santos, Janelle, Szymanski, Linda M. , Enninga, Elizabeth Ann L. , Mcduffie, Molly, Bulawa‐Regner, Lainee A., Cheek‐Norgan, E. Heidi, Lamppa, Julie A., Wick, Myra , Theiler, Regan N. , Bulawa-Regner, Lainee A, Cheek-Norgan, E Heidi, Enninga, Elizabeth Ann L , Norgan, Andrew P. , Mcduffie, Molly

Mayo Clinic

Pregnancy | May 5, 2025 | Volume: 1 | Issue: 3 | Pages: No page available

10.1002/pmf2.70029 | PMID 42597113 Get It

Abstract Obstetric training programs typically offer limited formal education on placental pathology; yet, in practice, obstetric providers are expected to incorporate placental pathology findings into the overall evaluation of obstetric complications. In this narrative review, we briefly review pathology classifications and then delve deeper into pathology findings that may change clinical decision‐making, specifically highlighting pathologic lesions with a recurrence risk and recommended management for subsequent pregnancies. Last, we present specific recommendations on how to improve clinical interpretability and utility of placental pathology reports for obstetrical practice.
Deucravacitinib in patients with inflammatory bowel disease: 12-week efficacy and safety results from 3 randomized phase 2 studies in Crohn’s disease and ulcerative colitis
D’Haens, Geert , Panaccione, Remo , Matsuoka, Katsuyoshi , Loftus, Edward V. , Kobayashi, Taku , Elsharkawi, Walid, Miceli, Rosa, Ahmed, Samia A. , Napoli, Andrew, Vaile, John, Dornic, Quentin, Patel, Aditya , Danese, Silvio , Panaccione, Remo , Kobayashi, Taku , Schreiber, Stefan , Loftus, Edward V , Danese, Silvio , Rubin, David T. , Peyrin‐Biroulet, Laurent , Luo, Yi , Matsuoka, K

Mayo Clinic

Journal of Crohn's and Colitis | May 3, 2025 | Volume: 19 | Issue: 6 | Pages: No page available

10.1093/ecco-jcc/jjaf080 | PMID 40355364 Get It

Abstract Background and Aims Tyrosine kinase 2 is a downstream intracellular mediator of interleukin-23 signaling, which has a key role in the pathogenesis of inflammatory bowel disease. Deucravacitinib is a novel, oral, selective, allosteric tyrosine kinase 2 inhibitor currently approved for the treatment of adults with moderate to severe plaque psoriasis. Methods Here we describe 3 randomized, double-blind, placebo-controlled phase 2 studies of deucravacitinib in patients with moderately to severely active Crohn’s disease (LATTICE-CD [NCT03599622]) or ulcerative colitis (LATTICE-UC [NCT03934216] and IM011-127 [NCT04613518]). Patients were randomized to receive placebo or twice-daily deucravacitinib 3 or 6 mg (LATTICE-CD), 6 mg (LATTICE-UC), or 12 mg (IM011-127) for 12 weeks. Coprimary endpoints for LATTICE-CD were clinical remission and endoscopic response at week 12. The primary endpoint was clinical remission (per modified Mayo score) at week 12 for LATTICE-UC and clinical response (per modified Mayo score) at week 12 for IM011-127. Results A total of 239 (LATTICE-CD), 131 (LATTICE-UC), and 38 (IM011-127) patients were randomized. The primary endpoints were not met for all 3 studies, which resulted in early study termination for LATTICE-CD and IM011-127. High efficacy rates were observed in placebo groups throughout the studies. In all studies, the safety profile of deucravacitinib was consistent with the known safety profile observed in patients with psoriasis, and no new safety signals were observed. Conclusions Deucravacitinib at multiple doses did not demonstrate significant clinical benefit vs placebo in moderately to severely active Crohn’s disease or ulcerative colitis. Deucravacitinib was safe and well tolerated.
Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Update
Garje, Rohan , Riaz, Irbaz Bin , Naqvi, Syed Arsalan Ahmed , Rumble, R. Bryan , Taplin, Mary‐Ellen , Kungel, Terry M. , Herchenhorn, Daniel , Zhang, Tian , Beckermann, Kathryn E. , Vapiwala, Neha , Celano, Paul , Hotte, Sebastién J. , Borno, Hala T. , Bryce, Alan H. , Wulff‐Burchfield, Elizabeth , He, Huan, Williams, J.E. Caerwyn , Hotte, Sebastien J , Basu, Arnab , Borno, Hala , Bryce, Alan H , Wulff-Burchfield, Elizabeth , Bodei, Lisa , Hamilton, Robert J , Emamekhoo, Hamid , Hope, Thomas A , Murad, M Hassan , Liu, Hongfang , Williams, James E , Parikh, Rahul A , Garje, Rohan , Herchenhorn, Daniel , He, Huan , Riaz, Irbaz B , Beckermann, Katy , Rumble, R Bryan , Carducci, Michael A. , Basu, Arnab , Wang, Peng , Bodei, Lisa , Loblaw, Andrew , Emamekhoo, Hamid , Hope, Thomas A. , Murad, M. Hassan , Liu, Hongfang

Mayo Clinic

Journal of Clinical Oncology | May 2, 2025 | Volume: 43 | Issue: 20 | Pages: 2311-2334

10.1200/jco-25-00007 | PMID 40315400 Get It

ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO Guidelines Methodology Manual . ASCO Guidelines follow the ASCO Conflict of Interest Policy for Clinical Practice Guidelines . Clinical Practice Guidelines and other guidance (“Guidance”) provided by ASCO is not a comprehensive or definitive guide to treatment options. It is intended for voluntary use by clinicians and should be used in conjunction with independent professional judgment. Guidance may not be applicable to all patients, interventions, diseases or stages of diseases. Guidance is based on review and analysis of relevant literature, and is not intended as a statement of the standard of care. ASCO does not endorse third-party drugs, devices, services, or therapies and assumes no responsibility for any harm arising from or related to the use of this information. See complete disclaimer in Appendix 1 and 2 (online only) for more . PURPOSE To provide evidence-based recommendations for patients with metastatic castration-resistant prostate cancer (mCRPC). METHODS An Expert Panel including patient representation completed a systematic review of the evidence and made recommendations. RESULTS Depending upon prior treatment received, androgen receptor pathway inhibitors (ARPIs: enzalutamide, abiraterone with prednisone), poly(ADP-ribose) polymerase inhibitors (PARPi), chemotherapeutic agents (docetaxel, cabazitaxel), radiopharmaceuticals (radium 223, 177 Lu-prostate-specific membrane antigen [PSMA]-617), and sipuleucel-T have demonstrated an overall survival (OS) benefit for patients with mCRPC. For patients with BRCA1 / 2 alterations who did not receive prior ARPI, the combination of PARPi and ARPI (talazoparib + enzalutamide, olaparib and/or niraparib + abiraterone) has shown clinical benefit. For patients with BRCA1 / 2 alterations who received prior ARPI or ARPI followed by docetaxel, olaparib showed OS benefit. In select patients with microsatellite instability-high/mismatch repair-deficient, pembrolizumab showed clinical efficacy. RECOMMENDATIONS Prior systemic therapy for castration-sensitive prostate cancer will determine subsequent therapy used for mCRPC. Continue androgen-deprivation therapy for patients with mCRPC indefinitely. Early adoption of somatic genetic testing and palliative care is recommended. Patients with mCRPC and bony metastases should receive a bone-protective agent. The panel recommends the combination of ARPI with PARPi in patients with BRCA1 / 2 alterations who did not receive prior ARPI. For patients who received prior ARPI, the panel recommends docetaxel chemotherapy. The panel recommends 177 Lu-PSMA-617 or cabazitaxel chemotherapy for patients who receive prior ARPI and docetaxel chemotherapy. For patients with BRCA1 / 2 alterations who received prior ARPI, the panel recommends PARPi monotherapy. Radium 223 is recommended for patients with symptomatic bone–only disease. Evidence for optimal sequencing for mCRPC regimens is lacking. Additional information is available at www.asco.org/genitourinary-cancer-guidelines .
Development of Rifampicin Eye Drops for the Treatment of Exudative Age-Related Macular Degeneration
Vailoces, Valory Anne Sarmiento , Tolentino, Andrew J., Arévalo, J. Fernando , Adelman, Ron A. , Bhisitkul, Robert B. , Diana, V., Nguyen, Quan Dong , Tolentino, Michael J. , Tanito, Masaki , Serizawa, Hiroaki, Arevalo, Jose Fernando

Mayo Clinic

Pharmaceuticals | May 2, 2025 | Volume: 18 | Issue: 5 | Pages: 655

10.3390/ph18050655 | PMID 40430474 Get It

Background/Objectives: Exudative age-related macular degeneration (AMD) is a disease of choroidal neovascularization that causes blindness. Current treatments to preserve vision in this prevalent and blinding condition are repeat intraocular injections of anti-vascular endothelial growth factor medicines for a patient’s lifetime to preserve and prevent vision loss leading to blindness. Rifampicin, a small-molecule antibiotic, has previously been reported to exhibit anti-angiogenic properties and a topical safety profile that is well-tolerated. Based on this evidence, we investigated the feasibility of formulating rifamycin as an ophthalmic drop capable of delivering therapeutic concentrations to the posterior segment of the eye. Methods: Inhibition of neovascularization by administration of rifampicin was analyzed in the rat oxygen-induced retinopathy (OIR) and mouse laser-induced choroidal neovascularization (CNV) models. Pharmacokinetic (PK) studies were conducted in mice, rats, and rabbits by dosing various formulations containing rifampicin, and the compound was quantified by LC/MS analysis. Results: Results from dose escalation studies in the mouse laser-induced CNV model suggested the minimum effective dose of rifampicin required for inhibiting neovascularization in subretinal tissues to be 0.7 mg/kg, which is substantially lower than the 20 mg/kg dosage approved for infectious disease treatments. The previous studies did not report the minimum effective dose in the anti-angiogenesis effects. The effective area under the concentration-time curve (AUC) in the sub-retina was evaluated as 0.27 h·ng/mg. In rabbits, rifampicin was delivered to the sub-retina by a single topical application of various formulations in a dose-dependent manner. The topical application of the formulations containing 1% rifampicin, which was well-tolerated in clinical trials previously reported for ocular trachoma, achieved subretinal delivery approximately 2–32 times greater than the effective AUC. Plasma exposure of the compound by the topical application was evaluated to range approximately 0.5–10 ng/mL. Conclusions: Rifampicin was delivered to the sub-retina in rabbits with an efficiency greater than the effective dose required for inhibiting neovascularization. Limited amounts of plasma exposure by the topical application were detected. These results suggested the therapeutic potential of the rifampicin formulations for the topical treatment of exudative macular degeneration.
Sleep trajectories across three cognitive‐aging pathways in community older adults
Oryshkewych, Nina , Wheeler, Bradley J. , Butters, Meryl A. , Buysse, Daniel J., Leng, Yue , Yu, Lan , Soehner, Adriane M. , Wallace, Meredith L. , Tapia, Amanda L. , Zaheed, Afsara B. , Buysse, Daniel J. , Barnes, Lisa L. , Lim, Andrew S. P.

Mayo Clinic

Alzheimer's & Dementia | May 2, 2025 | Volume: 21 | Issue: 5 | Pages: No page available

10.1002/alz.70159 | PMID 40317639 Get It

AbstractINTRODUCTIONComparing sleep and rest–activity rhythms across different cognitive aging pathways can identify novel risk factors and potential mechanisms. However, our current understanding is restricted by differences in sleep measurement, limited longitudinal data, and heterogeneous cognitive aging processes.METHODSWe applied cubic splines to longitudinal self‐reported sleep and actigraphy data from 1449 participants in the Rush Memory and Aging Project and quantified differences in the levels and trajectories of sleep amount, regularity, and timing within and between three cognitive aging pathways: normal, stable mild cognitive impairment, dementia.RESULTSSleep amount was lowest in the dementia pathway prior to cognitive impairment but increased with age, most rapidly after dementia. Regularity declined across all pathways, most rapidly after cognitive diagnoses. Timing advanced across all pathways.DISCUSSIONShorter sleep amount in cognitively healthy older adults may be a risk factor or prodromal indicator of dementia, while longer sleep amounts and decreasing regularity may reflect neurodegeneration.Highlights We quantified longitudinal changes in sleep across three cognitive‐aging pathways. We incorporated both subjective and objective measures of sleep health. Self‐report duration increased noticeably from before to after cognitive diagnosis. Sleep irregularity increased most prominently after cognitive diagnosis. Advances in sleep timing occurred in both normal and pathological aging.
From Theory to Practice: Moving Toward Artificial Intelligence–powered Computer Vision Applications for Peripheral Motor Nerve Assessment of the Hand
Rames, Jess D. , Tunaboylu, Mehmet Furkan , Emanuels, Andrew, Moran, Steven L. , Tunaboylu, Mehmet F., Emanuels, Andrew F.

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | May 1, 2025 | Volume: 13 | Issue: 4 | Pages: e6674

10.1097/gox.0000000000006674 | PMID 40196170 Get It

Summary: Computer vision has emerged as a useful technology that may prove capable of facilitating remote clinical examinations in hand surgery. This study’s primary aim is to evaluate the efficacy of computer vision for assessing peripheral motor function and range of motion of the hand for future clinic and telemedicine purposes. Five healthy volunteer subjects (10 hands total) were filmed performing three static hand examinations (“peace sign,” “hitchhiker thumb,” and “OK sign”) as well as apposition. Videos were processed using the proprietary H.AI.ND program based on the MediaPipe API (Google, v0.9.2.1), generating temporal and spatial data for joint angle analysis. The median joint angles determined for each test were compared with their manually derived counterparts to assess accuracy and reliability. The measurements were compared at a population level using Wilcoxon signed rank tests and at the individual video level using interclass correlation analyses. The artificial intelligence–generated angle outputs demonstrated a high level of reliability when compared with manually determined measurements for the 3 clinical positions included in this study. Assessment of compound appositional movement also demonstrated high reliability with time-dependent multijoint evaluation. Goniometric analysis through computer vision applications may provide an easy and reliable alternative for hand evaluation in the normal population for both static and dynamic function. Further study is warranted to evaluate this program’s potential role for diagnostic assessment in the diseased population before and after surgical investigation.
Higher risk of recurrence in partially thrombosed cerebral aneurysms post-WEB (Woven EndoBridge) device treatment: insights from the WorldWideWEB Consortium registry
Saliou, Guillaume , Salim, Hamza , Musmar, Basel , Adeeb, Nimer , Aslan, Assala , Swaid, Christian, Cuellar, Miguel, Dibas, Mahmoud , Cancelliere, Nicole M , Diestro, Jose Danilo Bengzon , Lay, Sovann V. , Guenego, Adrien , Möhlenbruch, Markus , Kral, Michael , Salem, Mohamed M , Foreman, Paul M. , Shaikh, Hamza , Župančić, Vedran , Rabinov, James D. , Ren, Yifan , Michelozzi, Caterina , Starke, Robert M. , Ogilvie, Mark , Nguyên, Anh , Jones, Jesse , Brinjikji, Waleed , Nawka, Marie Teresa , Psychogios, Marios‐Nikos , Ulfert, Christian , Pukenas, Bryan , Burkhardt, Jan Karl, Slawski, Diana , Pulli, Benjamin , Lubicz, Boris , Puri, Ajit S , Pero, Guglielmo , Raz, Eytan , Asadi, Hamed , Siddiqui, Adnan H. , Haranhalli, Neil , Altschul, David , Ducruet, Andrew F. , Albuquerque, Felipe C , Regenhardt, Robert W. , Stapleton, Christopher J. , Kan, Peter , Kalousek, Vladimir , Lylyk, Pedro , Boddu, Srikanth , Knopman, Jared , Tjoumakaris, Stavropoula , Jabbour, Pascal , Clarençon, Frédéric , Patel, Aman B. , Salim, Hamza , Ghozy, Sherief , Lay, Sovann V , Guenego, Adrien , Carnevale, Joseph Anthony , ElNaamani, Kareem , Shotar, Eimad , Chung, Charlotte , Salem, Mohamed M , Lylyk, Ivan , Shaikh, Hamza A , Hafeez, Muhammad U , Catapano, Joshua S , Ren, Yifan , Schirmer, Clemens M , Michelozzi, Caterina , Hassan, Ameer E , Ogilvie, Mark , Nguyen, Anh , Jones, Jesse , Brinjikji, Waleed , Nawka, Marie Teresa , Huynh, Thien J, Martinez-Gutierrez, Juan Carlos , Essibayi, Muhammed Amir , Sheth, Sunil A , Tawk, Rabih G , Pulli, Benjamin , Pero, Guglielmo , Raz, Eytan , Griessenauer, Christoph J , Siddiqui, Adnan H , Levy, Elad I , Albuquerque, Felipe C , Stapleton, Christopher , Kan, Peter , Kalousek, Vladimir , Tjoumakaris, Stavropoula , Cuellar-Saenz, Hugo H , Jabbour, Pascal , Dmytriw, Adam A , Hajdu, Steven D , Dibas, Mahmoud , Diestro, Jose Danilo B , Saliou, Guillaume , Altschul, David J , Musmar, Basel , Regenhardt, Robert W , Cancelliere, Nicole M , Ulfert, Christian , Burkhardt, Jan‐Karl , Cuellar, Miguel, Algin, Oktay , Ghozy, Sherief , Renieri, Leonardo , Mastorakos, Panagiotis , Naamani, Kareem El , Shotar, Eimad , Lylyk, Iván , Hafeez, Muhammad Ubaid , Waqas, Muhammad , Arslan, Muhammet , Ergün, Onur , Schirmer, Clemens M. , Piano, Mariangela , Kühn, Anna Luisa , Hassan, Ameer E , Huynh, Thien , Essibayi, Muhammed Amir , Tawk, Rabih G. , Panni, Pietro , Griessenauer, Christoph J. , Levy, Elad I. , Cuellar, Hugo , Limbucci, Nicola , Mendes Pereira, Vitor , Dmytriw, Adam A.

Mayo Clinic

Journal of NeuroInterventional Surgery | April 30, 2025 | Volume: 18 | Issue: 3 | Pages: 782-789

10.1136/jnis-2024-022628 | PMID 40306928 Get It

Background The Woven EndoBridge (WEB) device is a prevalent treatment for intracranial aneurysms. While many studies have assessed the obliteration rate post-WEB embolization, few have focused on long-term outcomes in partially thrombosed aneurysms. Objective To assess whether partially thrombosed aneurysms are at higher risk of recurrence or retreatment following WEB embolization compared with non-thrombosed aneurysms. Methods We evaluated data from 22 academic institutions, focusing on previously untreated cerebral aneurysms treated with the WEB device. Logistic regression was utilized to analyze factors predicting long-term aneurysm obliteration and retreatment necessity. Results Among 1303 patients, 26 presented with a partially thrombosed aneurysm. In the partially thrombosed group, the mean aneurysm maximal diameter was 10.7±4 mm with a neck ratio of 1.99±1.19 mm, larger than in the control group where the mean aneurysm maximal diameter was 6.81±2.37 mm with a neck ratio of 1.64±0.51 mm (P<0.001 for both maximal diameter and neck ratio). At the final follow-up, partially thrombosed aneurysms treated by the WEB device had a 38.5% retreatment rate, compared with 7.0% for non-thrombosed aneurysms (P<0.001). Among partially thrombosed aneurysms, the Raymond-Roy type IIIa/b occlusion rate was higher (38.5% vs 9.9%, P<0.001). On multivariate analysis, partially thrombosed aneurysms compared with non-thrombosed aneurysms had an increased rate of retreatment (OR 3.64, 95% CI 1.28 to 10.1). Conclusion Partially thrombosed aneurysms are associated with a poorer occlusion rate and a higher rate of retreatment following WEB embolization. For partially thrombosed aneurysms, the WEB device appears suboptimal as a first-line treatment, and therefore alternative techniques should be prioritized.
Current State of Baseball Interval Throwing Programs: A Systematic Review of Content, Structure, and Variability of Published Throwing Programs
Iyer, Sanathan, Simon, Karissa N. , Cherny, Chad E., Johnson, Andrew , Zajac, John M., Christoffer, Daniel J., Hellem, Aaron R., Finck, Adam N., Langhans, Mark T. , Boos, Alexander M. , Johnson, Andrew J, Camp, Christopher L. , Iyer, Sanathan, Johnson, Andrew J., Johnson, Andrew

Mayo Clinic

Sports Health: A Multidisciplinary Approach | April 29, 2025 | Volume: 17 | Issue: 6 | Pages: 1214-1224

10.1177/19417381251333402 | PMID 40298098 Get It

Context: There is need for an up-to-date comprehensive review of baseball interval throwing programs in the literature. Objective: To (1) understand the origin and basis of interval throwing programs; (2) evaluate the content of programs in the peer-reviewed literature including target audience, initiation criteria, throwing specifics, arm care, and performance evaluation metrics; (3) classify these variables as well defined, ambiguous, or missing; and (4) analyze variability in key aspects including starting criteria, length, progression, and completion criteria. Data Sources: Medline, Embase, Cochrane Reviews, Web of Science, and Scopus Study Selection: The full text of studies, in English, had to be available. Included studies had to contain a complete interval throwing program designed for baseball players. Study Design: Systematic review. Level of Evidence: Level 4. Data Extraction: Initial screening was conducted based on article title and abstract. Full text of the remaining articles was evaluated for fulfillment of inclusion criteria. Results: Nine studies initially met inclusion criteria. The programs’ comprehensiveness was poor, with a mean Interval Throwing Program Checklist score of 20 (range 14-23) on a scale of 0 to 30. There were a variety of components, including progressive long toss, weighted ball, and throwing mechanics exercises. The programs identified had significant heterogeneity in duration, intensity, progression, and focus. Overall, there was a significant lack of attempts at validation or formal study of efficacy for published throwing programs. Conclusion: Current published interval throwing programs are mostly variations of an original program published many years ago and were based on principles of progressive loading with pain as sign of injury that should be monitored carefully. However, these programs have minimal clinical validation and objective measures to quantify their effectiveness. This work identifies several limitations in the current literature and can serve as a foundation for future development of evidence-based interval throwing programs.
Concurrent Apixaban With Itraconazole or Posaconazole Pharmacokinetic and Clinical Outcome Evaluation in Cardiothoracic Transplant Recipients
Concannon, Kennedy , Huntsman, R. G. , Mara, Kristin C. , Kennedy, Cassie C. , Rosenbaum, Andrew , Lemke, Adley , Huntsman, Rachel , Mara, Kristin C , Kennedy, Cassie C , Lemke, Adley I

Mayo Clinic

Clinical Transplantation | April 28, 2025 | Volume: 39 | Issue: 5 | Pages: No page available

10.1111/ctr.70165 | PMID 40294102 Get It

ABSTRACTItraconazole and posaconazole are frequently prescribed following transplantation to prevent and treat fungal infections. Navigating drug interactions is challenging due to these agents’ potent CYP3A4 inhibition, and literature describing concurrent apixaban, a CYP3A4 substrate, is limited. This retrospective study of cardiothoracic transplant recipients evaluates the impact of itraconazole and posaconazole on apixaban exposure and reports clinical outcomes from routine apixaban dose reduction. Institutional practice reduces apixaban to 2.5 mg twice daily with itraconazole or posaconazole and obtains apixaban therapeutic drug monitoring (TDM), expected range 34–230 ng/mL. Eighteen levels collected in 15 patients on itraconazole displayed a median [IQR] apixaban trough of 143 ng/mL [95–195]. Fifteen levels collected in 13 patients on posaconazole displayed a median [IQR] apixaban trough of 124 ng/mL [93–174]. Two major bleed events, three VTE, two stroke, and eight instances of clot resolution were identified. Reduced‐dose apixaban resulted in apixaban exposure similar to normal dosing in the general population. Apixaban TDM is encouraged for individualized dosing when administered with itraconazole and posaconazole.
Development of Common Data Elements for Organ Transplantation
McElroy, Lisa M. , Rogers, Ursula , Nichols, Liz, Strauss, Alexandra T. , Ross‐Driscoll, Katie , Deirhoi-Reed, Rhiannon, Chan, Norine W. , Henson, Jackie B., Taber, D., Milam, Adam J. , Patzer, Rachel E. , Gagnon, Jennifer, Kirk, Allan D. , McElroy, Lisa M , Chan, Norine W , Milam, Adam J , Bhavsar, Nrupen Anjan , Schappe, Tyler , Harding, Jessica L. , Gordon, Elisa J. , Henson, Jackie B., Ng, Yue‐Harn , Schold, Jesse D , Caicedo, Juan Carlos , Adams, Andrew B. , Berchuck, Samuel I. , Matsouaka, Roland

Mayo Clinic

JAMA Network Open | April 28, 2025 | Volume: 8 | Issue: 4 | Pages: e257704

10.1001/jamanetworkopen.2025.7704 | PMID 40293753 Get It

This cohort study examines the validity of an electronic health record data model for organ transplantation.